Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
134.39
+0.11 (0.08%)
Jul 27, 2026, 3:44 PM EDT - Market open
Apogee Therapeutics Employees
Apogee Therapeutics had 261 employees as of December 31, 2025. The number of employees increased by 65 or 33.16% compared to the previous year.
Employees
261
Change (1Y)
65
Growth (1Y)
33.16%
Revenue / Employee
n/a
Profits / Employee
-$1,052,165
Market Cap
10.09B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 261 | 65 | 33.16% |
| Dec 31, 2024 | 196 | 105 | 115.38% |
| Dec 31, 2023 | 91 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Ionis Pharmaceuticals | 1,402 |
| Corcept Therapeutics | 730 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Summit Therapeutics | 265 |
| Kymera Therapeutics | 253 |
APGE News
- 13 days ago - Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals - ETF Trends
- 14 days ago - Apogee Therapeutics Proxy statement: Proxy filing - Filings
- 25 days ago - Apogee Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Healthcare stocks have become a haven for investors ditching tech - Market Watch
- 4 weeks ago - Apogee Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Biotech ETF Index Surges 10% After Rebalance - ETF Trends
- 4 weeks ago - AbbVie's $11 Billion Immunology Bet - Forbes
- 4 weeks ago - Apogee Therapeutics downgraded to Hold from Buy at Stifel - TheFly